Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Denali Therapeutics (DNLI) EBITDA Margin (2018 - 2023)

Historic EBITDA Margin for Denali Therapeutics (DNLI) over the last 6 years, with Q3 2023 value amounting to 7779.24%.

  • Denali Therapeutics' EBITDA Margin fell 48886000.0% to 7779.24% in Q3 2023 from the same period last year, while for Jun 2024 it was 33218.0%, marking a year-over-year decrease of 331837400.0%. This contributed to the annual value of 41.66% for FY2023, which is 2629400.0% up from last year.
  • Per Denali Therapeutics' latest filing, its EBITDA Margin stood at 7779.24% for Q3 2023, which was down 48886000.0% from 62.71% recorded in Q2 2023.
  • In the past 5 years, Denali Therapeutics' EBITDA Margin registered a high of 77.22% during Q4 2020, and its lowest value of 7779.24% during Q3 2023.
  • Moreover, its 5-year median value for EBITDA Margin was 883.86% (2021), whereas its average is 1185.31%.
  • Per our database at Business Quant, Denali Therapeutics' EBITDA Margin skyrocketed by 29333400bps in 2019 and then tumbled by -48886000bps in 2023.
  • Denali Therapeutics' EBITDA Margin (Quarter) stood at 1160.89% in 2019, then skyrocketed by 107bps to 77.22% in 2020, then crashed by -899bps to 617.22% in 2021, then tumbled by -48bps to 911.32% in 2022, then plummeted by -754bps to 7779.24% in 2023.
  • Its EBITDA Margin was 7779.24% in Q3 2023, compared to 62.71% in Q2 2023 and 299.97% in Q1 2023.